Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Total Non-Current Liabilities (2017 - 2025)

Arcus Biosciences (RCUS) has 9 years of Total Non-Current Liabilities data on record, last reported at $373.0 million in Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities changed N/A year-over-year to $373.0 million; the TTM value through Dec 2025 reached $373.0 million, changed N/A, while the annual FY2025 figure was $373.0 million, N/A changed from the prior year.
  • Total Non-Current Liabilities reached $373.0 million in Q4 2025 per RCUS's latest filing, down from $386.0 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $733.0 million in Q1 2022 and bottomed at -$708.0 million in Q2 2025.
  • Average Total Non-Current Liabilities over 5 years is $427.0 million, with a median of $497.0 million recorded in 2022.
  • Peak YoY movement for Total Non-Current Liabilities: soared 646.09% in 2021, then plummeted 35.56% in 2025.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $628.4 million in 2021, then decreased by 19.96% to $503.0 million in 2022, then fell by 2.39% to $491.0 million in 2023, then grew by 22.0% to $599.0 million in 2024, then plummeted by 37.73% to $373.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Non-Current Liabilities were $373.0 million in Q4 2025, $386.0 million in Q3 2025, and -$708.0 million in Q2 2025.